In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology ...

On June 5–6, the Global Think-tank on Steatotic Liver Disease1 convened a multidisciplinary group of 125 participants in Barcelona, including clinicians, patient advocates, public health experts, and ...

And how reliably can these findings be related to the human observations? Most importantly, the chain of causality implied by the title is unproven: the key question of whether or not (somehow) ...

Following administration of a methionine and choline deficient (MCD) diet, mice rapidly and consistently develop a severe form of steatohepatitis. 10 The resulting characteristic pathology of ...

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their specific roles in the progression of disease remain unknown. To address this ...

People with MASLD and more so with metabolic dysfunction-associated steatohepatitis (MASH) and MASLD-associated hepatic fibrosis can progress to cirrhosis and hepatocellular carcinoma and are at ...

Pemafibrate + tofogliflozin is under clinical development by Kowa and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).